CN103189072A - 新型免疫刺激方法 - Google Patents
新型免疫刺激方法 Download PDFInfo
- Publication number
- CN103189072A CN103189072A CN2011800514616A CN201180051461A CN103189072A CN 103189072 A CN103189072 A CN 103189072A CN 2011800514616 A CN2011800514616 A CN 2011800514616A CN 201180051461 A CN201180051461 A CN 201180051461A CN 103189072 A CN103189072 A CN 103189072A
- Authority
- CN
- China
- Prior art keywords
- tlr2
- pam2cys
- experimenter
- mice
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 C*NC(CSCC(CO*C)O*C)C(O)=O Chemical compound C*NC(CSCC(CO*C)O*C)C(O)=O 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Otolaryngology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510939940.1A CN105477640B (zh) | 2010-09-22 | 2011-09-22 | 新型免疫刺激方法 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2010904284 | 2010-09-22 | ||
AU2010904284A AU2010904284A0 (en) | 2010-09-22 | Novel Immunostimulatory Method | |
AU2011902408 | 2011-06-20 | ||
AU2011902408A AU2011902408A0 (en) | 2011-06-20 | Novel immunstimulatory method | |
PCT/AU2011/001225 WO2012037612A1 (en) | 2010-09-22 | 2011-09-22 | Novel immunostimulatory method |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510939940.1A Division CN105477640B (zh) | 2010-09-22 | 2011-09-22 | 新型免疫刺激方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103189072A true CN103189072A (zh) | 2013-07-03 |
CN103189072B CN103189072B (zh) | 2018-02-09 |
Family
ID=45873313
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510939940.1A Active CN105477640B (zh) | 2010-09-22 | 2011-09-22 | 新型免疫刺激方法 |
CN201180051461.6A Active CN103189072B (zh) | 2010-09-22 | 2011-09-22 | 免疫刺激方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510939940.1A Active CN105477640B (zh) | 2010-09-22 | 2011-09-22 | 新型免疫刺激方法 |
Country Status (10)
Country | Link |
---|---|
US (5) | US9676819B2 (zh) |
EP (3) | EP3669892B1 (zh) |
JP (4) | JP2013537892A (zh) |
CN (2) | CN105477640B (zh) |
AU (1) | AU2011305061B2 (zh) |
CA (1) | CA2811957C (zh) |
DK (1) | DK2618842T3 (zh) |
ES (1) | ES2735274T3 (zh) |
PL (1) | PL2618842T3 (zh) |
WO (1) | WO2012037612A1 (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2011305061B2 (en) | 2010-09-22 | 2016-04-14 | Ena Respiratory Pty Ltd | Novel immunostimulatory method |
CN105555756B (zh) | 2013-06-28 | 2018-12-07 | 奥克兰联合服务有限公司 | 氨基酸缀合物和肽缀合物及缀合方法 |
US20170274068A1 (en) * | 2014-09-12 | 2017-09-28 | The University Of Melbourne | Immunological reagent |
BR112017013574A2 (pt) | 2014-12-23 | 2018-03-06 | Verdon Daniel | conjugados de aminoácido e peptídeo e usos dos mesmos |
JP7161404B2 (ja) | 2016-02-26 | 2022-10-26 | オークランド ユニサービシーズ リミティド | アミノ酸及びペプチド接合体及び接合方法 |
EP3600374B1 (en) * | 2017-03-31 | 2024-05-15 | ENA Respiratory Pty Ltd | Treatment of respiratory infection |
US20210177795A1 (en) * | 2017-12-21 | 2021-06-17 | Ena Therapeutics Pty Ltd | Administering compounds |
JP2022546806A (ja) * | 2019-09-04 | 2022-11-09 | アクセリア オンコロジー ピーティーワイ リミテッド | 癌免疫療法 |
EP4025203A4 (en) * | 2019-09-04 | 2023-12-20 | Axelia Oncology Pty Ltd | CANCER TREATMENT |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006091591A1 (en) * | 2005-02-22 | 2006-08-31 | The Regents Of The University Of California | Methods of treating gastrointestinal inflammation |
CN101121754A (zh) * | 2002-08-12 | 2008-02-13 | 昆士兰医学研究所理事会 | 含有辅助t细胞和b细胞表位的新的免疫原性脂肽 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4119856A1 (de) | 1991-06-17 | 1992-12-24 | Hoechst Ag | N-acyl-s-(2-hydroxyalkyl)-cysteine, deren herstellung sowie deren verwendung als zwischenprodukte zur herstellung von synthetischen immunadjuvantien und synthetischen impfstoffen |
WO2001037869A1 (en) | 1999-11-19 | 2001-05-31 | Csl Limited | Vaccine compositions |
CN1606446A (zh) * | 2000-05-19 | 2005-04-13 | 科里克萨有限公司 | 用单糖和二糖类化合物预防和治疗传染病和其他疾病的方法 |
EP1382352A1 (de) * | 2002-07-19 | 2004-01-21 | GBF Gesellschaft für Biotechnologische Forschung mbH | Bisacyloxypropylcystein-Konjugate und deren Verwendung |
KR101151368B1 (ko) | 2002-08-12 | 2012-06-08 | 더 카운실 오브 더 퀸스랜드 인스티튜트 오브 메디칼 리서어치 | T-헬퍼 및 세포독성 t 림프구(ctl) 에피토프를포함하는 신규한 면역원성 리포펩타이드 |
EP1550458A1 (en) | 2003-12-23 | 2005-07-06 | Vectron Therapeutics AG | Synergistic liposomal adjuvants |
CN1921877A (zh) * | 2004-01-16 | 2007-02-28 | 悉生物有限公司 | 陪伴蛋白10对Toll样受体诱导的细胞因子和趋化因子分泌的调节 |
WO2005079419A2 (en) | 2004-02-17 | 2005-09-01 | The Regents Of The University Of California | Methods of treating immunopathological disorders |
GB0405634D0 (en) | 2004-03-12 | 2004-04-21 | Univ Southampton | Anti-virus therapy for respiratory diseases |
GB0411411D0 (en) | 2004-05-21 | 2004-06-23 | Glaxosmithkline Biolog Sa | Vaccines |
CN101437964B (zh) | 2004-10-18 | 2012-06-13 | 全球免疫股份有限公司 | 基于酵母的对慢性丙型肝炎感染的治疗 |
EP1666056A1 (en) | 2004-12-06 | 2006-06-07 | Bestewil Holding B.V. | Cancer vaccine vesicles |
EP1831259A2 (en) | 2004-12-21 | 2007-09-12 | Vaxinnate Corporation | Compositions of influenza viral proteins and methods of use thereof |
BRPI0607605A2 (pt) | 2005-02-08 | 2009-09-15 | Queensland Inst Med Res | moléculas imunogênicas |
US20080170996A1 (en) | 2006-07-28 | 2008-07-17 | The Board Of Regents Of The University Of Texas System | Compositions and Methods for Stimulation of Lung Innate Immunity |
CA2702154C (en) * | 2007-10-09 | 2017-05-16 | The University Of Melbourne | A method of transfection and compositions therefor |
WO2009137103A2 (en) | 2008-05-09 | 2009-11-12 | Ourth Donald D | Anti-cancer/anti-viral compounds and methods of use |
US8728465B2 (en) | 2008-06-17 | 2014-05-20 | Cedars-Sinai Medical Center | Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors |
CA2736187A1 (en) | 2008-09-05 | 2010-03-11 | Id Biomedical Corporation Of Quebec | Novel compositions and adjuvants |
KR20110117705A (ko) | 2009-02-11 | 2011-10-27 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 톨-유사 수용체 조정제 및 질병의 치료 |
JP5759445B2 (ja) | 2009-03-25 | 2015-08-05 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 病原体に対する哺乳類先天性免疫抵抗性の刺激のための組成物 |
JP2012523379A (ja) | 2009-04-09 | 2012-10-04 | ザ ユニバーシティー オブ メルボルン | 免疫原性組成物およびその使用 |
EP2338521A1 (en) | 2009-12-28 | 2011-06-29 | Helmholtz-Zentrum für Infektionsforschung GmbH | Lipopeptide- and lipoprotein-conjugates and its use |
KR101853513B1 (ko) | 2010-03-23 | 2018-04-30 | 노파르티스 아게 | 감염, 염증, 호흡기 질환 등의 치료를 위해 사용되는 tlr2 효능제로서의 화합물 (시스테인 기재 리포펩티드) 및 조성물 |
AU2011305061B2 (en) | 2010-09-22 | 2016-04-14 | Ena Respiratory Pty Ltd | Novel immunostimulatory method |
US20170274068A1 (en) | 2014-09-12 | 2017-09-28 | The University Of Melbourne | Immunological reagent |
-
2011
- 2011-09-22 AU AU2011305061A patent/AU2011305061B2/en active Active
- 2011-09-22 PL PL11826223T patent/PL2618842T3/pl unknown
- 2011-09-22 DK DK11826223.7T patent/DK2618842T3/da active
- 2011-09-22 EP EP20155567.9A patent/EP3669892B1/en active Active
- 2011-09-22 CA CA2811957A patent/CA2811957C/en active Active
- 2011-09-22 CN CN201510939940.1A patent/CN105477640B/zh active Active
- 2011-09-22 EP EP19163679.4A patent/EP3520814A1/en not_active Withdrawn
- 2011-09-22 WO PCT/AU2011/001225 patent/WO2012037612A1/en active Application Filing
- 2011-09-22 CN CN201180051461.6A patent/CN103189072B/zh active Active
- 2011-09-22 EP EP11826223.7A patent/EP2618842B1/en active Active
- 2011-09-22 US US13/825,679 patent/US9676819B2/en active Active
- 2011-09-22 ES ES11826223T patent/ES2735274T3/es active Active
- 2011-09-22 JP JP2013529510A patent/JP2013537892A/ja not_active Withdrawn
-
2016
- 2016-11-04 JP JP2016216593A patent/JP6657507B2/ja active Active
-
2017
- 2017-05-16 US US15/596,427 patent/US10406100B2/en active Active
-
2019
- 2019-07-26 US US16/522,779 patent/US11351114B2/en active Active
-
2021
- 2021-06-03 JP JP2021093836A patent/JP2021130713A/ja not_active Withdrawn
-
2022
- 2022-05-24 US US17/664,717 patent/US11786458B2/en active Active
-
2023
- 2023-06-09 JP JP2023095418A patent/JP2023113902A/ja active Pending
- 2023-10-10 US US18/483,662 patent/US20240050364A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101121754A (zh) * | 2002-08-12 | 2008-02-13 | 昆士兰医学研究所理事会 | 含有辅助t细胞和b细胞表位的新的免疫原性脂肽 |
WO2006091591A1 (en) * | 2005-02-22 | 2006-08-31 | The Regents Of The University Of California | Methods of treating gastrointestinal inflammation |
Also Published As
Publication number | Publication date |
---|---|
CN103189072B (zh) | 2018-02-09 |
US9676819B2 (en) | 2017-06-13 |
EP2618842A1 (en) | 2013-07-31 |
CN105477640A (zh) | 2016-04-13 |
US10406100B2 (en) | 2019-09-10 |
JP2013537892A (ja) | 2013-10-07 |
CA2811957C (en) | 2019-04-16 |
JP2023113902A (ja) | 2023-08-16 |
JP2019167369A (ja) | 2019-10-03 |
US20220296505A1 (en) | 2022-09-22 |
WO2012037612A1 (en) | 2012-03-29 |
US20130230544A1 (en) | 2013-09-05 |
PL2618842T3 (pl) | 2019-10-31 |
CN105477640B (zh) | 2019-09-17 |
US20240050364A1 (en) | 2024-02-15 |
EP3669892A1 (en) | 2020-06-24 |
JP2021130713A (ja) | 2021-09-09 |
US20190380952A1 (en) | 2019-12-19 |
JP6657507B2 (ja) | 2020-03-04 |
JP2017061504A (ja) | 2017-03-30 |
US11351114B2 (en) | 2022-06-07 |
EP2618842B1 (en) | 2019-04-24 |
ES2735274T3 (es) | 2019-12-17 |
AU2011305061A1 (en) | 2013-05-02 |
CA2811957A1 (en) | 2012-03-29 |
EP2618842A4 (en) | 2014-03-26 |
DK2618842T3 (da) | 2019-07-01 |
EP3520814A1 (en) | 2019-08-07 |
AU2011305061B2 (en) | 2016-04-14 |
US11786458B2 (en) | 2023-10-17 |
US20170246312A1 (en) | 2017-08-31 |
EP3669892B1 (en) | 2024-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103189072A (zh) | 新型免疫刺激方法 | |
US11918645B2 (en) | Vaccines against hepatitis B virus | |
JP2021001216A (ja) | インフルエンザ抗原送達用のベクターおよび構築体 | |
CN102316896A (zh) | 疫苗 | |
CN1901935A (zh) | 具有改进耐受性的免疫原组合物中的疏水性蛋白调配物 | |
AU2008311897B2 (en) | Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes | |
Uchida et al. | Application of surface-linked liposomal antigens to the development of vaccines that induce both humoral and cellular immunity | |
JP7497962B2 (ja) | 新規な免疫賦活法 | |
AU608354B2 (en) | Vaccination against rabies-related viruses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20170823 Address after: Victoria, Australia Applicant after: Innawak Pte. Ltd. Address before: Vitoria, Australia Applicant before: THE University OF MELBOURNE |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: Vitoria, Australia Patentee after: Axelia oncology Pte. Ltd. Address before: Vitoria, Australia Patentee before: Ena Therapeutics Pty Ltd. Address after: Vitoria, Australia Patentee after: Ena Therapeutics Pty Ltd. Address before: Vitoria, Australia Patentee before: Innawak Pte. Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230103 Address after: New South Wales,Australia Patentee after: Aina Breathing Pte. Ltd. Address before: Vitoria, Australia Patentee before: Axelia oncology Pte. Ltd. |
|
TR01 | Transfer of patent right |